Announcements Trials
Browse Landscape

Phase

Phase 2 26Phase 1 7Phase 3 4Phase 1/2 4Phase NA 2Phase EARLY_PHASE1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 5Thoracic 3Gastrointestinal 3Head & Neck 2Genitourinary 2Breast 2Sarcoma 1Other solid neoplasm 1Endocrine 1

Conditions

Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Breast Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 6pembrolizumab 3Specimen Handling 3Radiotherapy 3Oncolytic Virotherapy 3Nivolumab 3Irinotecan 3Cyclophosphamide 3X-Rays 2Temozolomide 2Etoposide 2Doxorubicin 2Biopsy 2Bevacizumab 2trastuzumab biosimilar HLX02 1sodium thiosulfate 1romiplostim 1pertuzumab 1perflutren 1palbociclib 1olaparib 1niraparib 1montelukast 1glucarpidase 1gamma-Glutamyl Hydrolase 1fluorodopa F 18 1eribulin 1entrectinib 1entacapone 1cobimetinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Paclitaxel × Sarcoma × Clear all
NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

OHSU Knight Cancer Institute

Phase EARLY_PHASE1 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡